

UNITED STATES INTERNATIONAL TRADE COMMISSION
Washington, D.C.

Investigation No. 332-610

Impact on U.S. Industry of China's State Support and Pricing Practices in the Biotechnology Sector

AGENCY: United States International Trade Commission

ACTION: Notice of Investigation and Scheduling of a Public Hearing

SUMMARY: The U.S. International Trade Commission has self-instituted Investigation No. 332-610, *Impact on U.S. Industry of China's State Support and Pricing Practices in the Biotechnology Sector*, to produce a report as directed by the U.S. Senate Committee on Appropriations reviewing the extent to which Chinese state support and pricing practices in the biotechnology sector may be affecting market share and competitiveness of the U.S. industry.

DATES:

May 11, 2026: Deadline for filing requests to appear at the public hearing

May 14, 2026: Deadline for filing prehearing briefs and statements

May 20, 2026: Deadline for filing electronic copies of hearing oral statements

May 27-28, 2026: Public hearing

June 11, 2026: Deadline for filing posthearing briefs

July 17, 2026: Deadline for filing all other written submissions

January 22, 2027: Anticipated date for publication of the report

ADDRESSES: All Commission offices, including the Commission's hearing rooms, are located in the U.S. International Trade Commission Building, 500 E Street SW, Washington, DC 20436. All written submissions should be addressed to the Secretary, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436. The public record for this investigation may be viewed on the Commission's electronic docket (EDIS) at <https://edis.usitc.gov>.

FOR FURTHER INFORMATION CONTACT: Project Leader Nathan Lotze (202-205-3231 or nathan.lotze@usitc.gov) or Deputy Project Leaders Lin Jones (202-205-3246 or lin.jones@usitc.gov) and Grace Robinson (202-205-3711 or grace.robinson@usitc.gov) for information specific to this investigation. For information on the legal aspects of this investigation, contact Brian Allen (202-205-3034 or brian.allen@usitc.gov) of the Commission's Office of the General Counsel. The media should contact Claire Huber, Office of External Relations (202-205-1819 or claire.huber@usitc.gov). Hearing-impaired individuals may obtain information on this matter by contacting the Commission's TDD terminal at 202-205-1810. General information concerning the Commission may also be obtained by accessing its website (<https://www.usitc.gov>). Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at 202-205-2000.

SUPPLEMENTARY INFORMATION:

Background: The Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026 (the Act), signed by the President on January 23, 2026, provides funding for the Commission for fiscal year 2026. Pub. L. 119-74. A report of the Senate Committee on Appropriations (Committee) accompanying the Act contains language directing the Commission to review the extent to which Chinese state support and pricing practices in the biotechnology sector may be affecting U.S. market share and competitiveness. The Committee in its report states that the Commission report in this investigation (1) should include detailed information, to the extent practicable, on the degree of subsidization and market overcapacity by Chinese biotechnology firms and its impact on U.S. industry, including genomic sequencing, synthetic biology, and active pharmaceutical ingredient manufacturing; (2) should examine the extent to which Chinese state support and pricing practices may be affecting U.S. market share and competitiveness in biotechnology-related products and services; and (3) should be transmitted to the House of Representatives and Senate Committees on Appropriations within 12 months of the Act's enactment. Departments of Commerce and Justice, Science, and Related Agencies Appropriations Bill, S. Rept. No. 119-44, at 174-75 (2025); 172 Cong. Rec. H255 (daily ed. Jan. 8, 2026).

The Commission is self-instituting this investigation under section 332(b) of the Trade Act of 1974 (19 U.S.C. 1332(b)) to produce a report containing information and analysis as detailed above and will publish its report no later than January 22, 2027.

Public hearing: A public hearing in connection with this investigation will be held beginning at 9:30 a.m., May 27, 2026, and continuing, if necessary, on May 28, 2026, in the Main Hearing Room of the U.S. International Trade Commission, 500 E Street SW, Washington DC 20436. The hearing can also be accessed remotely using the WebEx videoconference platform. A link to the hearing will be posted on the Commission's website at <https://www.usitc.gov/calendarpad/calendar.html>.

Requests to appear at the hearing should be filed with the Secretary to the Commission no later than 5:15 p.m., May 11, 2026, in accordance with the requirements in the "Written Submissions" section below. Any requests to appear as a witness via videoconference must be included with your request to appear. Requests to appear as a witness via videoconference must include a statement explaining why the witness cannot appear in person; the Chair, or other person designated to conduct the investigation, may at their discretion for good cause shown, grant such requests. Requests to appear as a witness via videoconference due to illness or a positive COVID-19 test result may be submitted by 3 p.m. the business day prior to the hearing.

All prehearing briefs and statements should be filed no later than 5:15 p.m., May 14, 2026. To facilitate the hearing, including the preparation of an accurate written public transcript of the hearing, a written copy of oral testimony to be presented at the hearing must be submitted to the Commission electronically no later than noon, May 20, 2026. All posthearing briefs and statements should be filed no later than 5:15 p.m., June 11, 2026. Posthearing briefs and statements should address matters raised at the hearing. For a description of the different types of written briefs and statements, see the "Definitions" section below.

In the event that, as of the close of business on May 11, 2026, no witnesses are scheduled to appear at the hearing, the hearing will be canceled. Any person interested in attending the hearing as an observer or nonparticipant should check the Commission website as indicated above for information concerning whether the hearing will be held.

Written submissions: In lieu of or in addition to participating in the hearing, interested persons are invited to file written submissions concerning this investigation. All written submissions should be addressed to the Secretary, and should be received no later than 5:15 p.m., July 17, 2026. All written submissions must conform to the provisions of section 201.8 of the Commission's *Rules of Practice and Procedure* (19 CFR 201.8). Filings must be made through the Commission's Electronic Document Information System (EDIS, <https://edis.usitc.gov>). Persons with questions regarding electronic filing should contact the Office of the Secretary, Docket Services Division (202–205–1802), email EDIS3help@usitc.gov, or consult the Commission's *Handbook on Filing Procedures*.

Definitions of types of documents that may be filed; Requirements: In addition to requests to appear at the hearing, this notice provides for the possible filing of four types of documents: prehearing briefs, hearing oral statements, posthearing briefs, and other written submissions.

(1) *Prehearing briefs* refers to written materials relevant to the investigation and submitted in advance of the hearing, and includes written views on matters that are the subject of the investigation, supporting materials, and any other written materials that you consider will help the Commission in understanding your views. You should file a prehearing brief particularly if you plan to testify at the hearing on behalf of an industry group, company, or other organization, and wish to provide detailed views or information that will support or supplement your testimony.

(2) *Hearing oral statements* refers to the actual oral statement that you intend to present at the hearing. Do not include any confidential business information (CBI) in that statement. If you plan to testify, you must file a written copy of your oral statement by the date specified in this notice. This statement will allow Commissioners to understand your position in advance of the hearing and will also assist the court reporter in preparing an accurate transcript of the hearing (*e.g.*, names spelled correctly).

(3) *Posthearing briefs* refers to submissions filed after the hearing by persons who appeared at the hearing. Such briefs: (a) should be limited to matters that arose during the hearing; (b) should respond to any Commissioner and staff questions addressed to you at the hearing; (c) should clarify, amplify, or correct any statements you made at the hearing; and (d) may, at your option, address or rebut statements made by other participants in the hearing.

(4) *Other written submissions* refers to any other written submissions that interested persons wish to make, regardless of whether they appeared at the hearing, and may include new information or updates of information previously provided.

In accordance with the provisions of section 201.8 of the Commission's *Rules of Practice and Procedure*, the document must identify on its cover (1) the investigation number and title and the

type of document filed (*i.e.*, prehearing brief, hearing oral statement of (name), posthearing brief, or written submission); (2) the name and signature of the person filing it; (3) the name of the organization that the submission is filed on behalf of; and (4) whether it contains CBI. If it contains CBI, it must comply with the marking and other requirements set out below in this notice relating to CBI. Submitters of written documents (other than hearing oral statements) are encouraged to include a short summary of their position or interest at the beginning of the document, and a table of contents when the document addresses multiple issues.

Confidential business information: Any submissions that contain CBI must also conform to the requirements of section 201.6 of the Commission's *Rules of Practice and Procedure* (19 CFR 201.6). Section 201.6 of the rules requires that the cover of the document and the individual pages be clearly marked as to whether they are the "confidential" or "nonconfidential" version, and that the CBI is clearly identified by means of brackets. All written submissions, except for CBI, will be made available for inspection by interested persons.

The Commission will not include any CBI in its report. However, all information, including CBI, submitted in this investigation may be disclosed to and used by: (i) the Commission, its employees and offices, and contract personnel (a) for developing or maintaining the records of this or a related proceeding, or (b) in internal investigations, audits, reviews, and evaluations relating to the programs, personnel, and operations of the Commission, including under 5 U.S.C. Appendix 3; or (ii) U.S. government employees and contract personnel for cybersecurity purposes. The Commission will not otherwise disclose any CBI in a way that would reveal the operations of the firm supplying the information.

Summaries of views of interested persons: Interested persons wishing to have a summary of their views included in the report should include a summary with a written submission on or before July 17, 2026, and should mark the summary as having been provided for that purpose. The summary should be clearly marked as "summary for inclusion in the report" at the top of the page. The summary may not exceed 500 words and should not include any CBI. The summary will be published as provided if it meets these requirements and is germane to the subject matter of the investigation. The Commission will list the name of the organization furnishing the summary and will include a link where the written submission can be found.

By order of the Commission.



Lisa R. Barton
Secretary to the Commission

Issued: February 26, 2026